Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Asset Utilization Ratio: 2015-2025

Historic Asset Utilization Ratio for CytomX Therapeutics (CTMX) over the last 10 years, with Sep 2025 value amounting to 0.68.

  • CytomX Therapeutics' Asset Utilization Ratio fell 19.71% to 0.68 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.68, marking a year-over-year decrease of 19.71%. This contributed to the annual value of 0.86 for FY2024, which is 95.86% up from last year.
  • Per CytomX Therapeutics' latest filing, its Asset Utilization Ratio stood at 0.68 for Q3 2025, which was down 33.91% from 1.03 recorded in Q2 2025.
  • CytomX Therapeutics' 5-year Asset Utilization Ratio high stood at 1.35 for Q1 2025, and its period low was 0.07 during Q1 2021.
  • Moreover, its 3-year median value for Asset Utilization Ratio was 0.68 (2025), whereas its average is 0.71.
  • As far as peak fluctuations go, CytomX Therapeutics' Asset Utilization Ratio crashed by 46.58% in 2021, and later skyrocketed by 142.48% in 2023.
  • Over the past 5 years, CytomX Therapeutics' Asset Utilization Ratio (Quarterly) stood at 0.11 in 2021, then surged by 107.75% to 0.22 in 2022, then surged by 119.38% to 0.48 in 2023, then surged by 122.38% to 1.06 in 2024, then decreased by 19.71% to 0.68 in 2025.
  • Its last three reported values are 0.68 in Q3 2025, 1.03 for Q2 2025, and 1.35 during Q1 2025.